{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:22:56Z","timestamp":1763662976702,"version":"3.45.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejps.2025.107314","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:46:32Z","timestamp":1760071592000},"page":"107314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and pharmacokinetics of escalating doses of recombinant human nerve growth factor eye drops (HT006.2.2) in healthy subjects"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1679-1508","authenticated-orcid":false,"given":"Yuyang","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1447-8895","authenticated-orcid":false,"given":"Feng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0890-674X","authenticated-orcid":false,"given":"Hongyan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3746-7184","authenticated-orcid":false,"given":"Siyang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4921-469X","authenticated-orcid":false,"given":"Xiaojun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2488-8592","authenticated-orcid":false,"given":"Ying","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8185-746X","authenticated-orcid":false,"given":"Huan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4235-0740","authenticated-orcid":false,"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7516-5238","authenticated-orcid":false,"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0433-4879","authenticated-orcid":false,"given":"Huadong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2649-8241","authenticated-orcid":false,"given":"Ying","family":"Jie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4439-9108","authenticated-orcid":false,"given":"Laichun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107314_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1210179","article-title":"Effect of recombinant human nerve growth factor treatment on corneal nerve regeneration in patients with neurotrophic keratopathy","volume":"17","author":"Balbuena-Pareja","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejps.2025.107314_bib0002","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1167\/iovs.12-10816","article-title":"Nerve growth factor promotes corneal epithelial migration by enhancing expression of matrix metalloprotease-9","volume":"54","author":"Blanco-Mezquita","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejps.2025.107314_bib0003","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.ophtha.2018.03.004","article-title":"Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis","volume":"125","author":"Bonini","year":"2018","journal-title":"Ophthalmology."},{"key":"10.1016\/j.ejps.2025.107314_bib0004","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","article-title":"Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis","volume":"125","author":"Bonini","year":"2018","journal-title":"Ophthalmology."},{"key":"10.1016\/j.ejps.2025.107314_bib0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.17116\/oftalma2022138061123","article-title":"[Modern capabilities in diagnosis and treatment of neurotrophic keratopathy]","volume":"138","author":"Brzheskiy","year":"2022","journal-title":"Vestn. Oftalmol."},{"key":"10.1016\/j.ejps.2025.107314_bib0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0006-8993(96)00905-5","article-title":"Complete recovery by nerve growth factor of neuropeptide content and function in capsaicin-impaired sensory neurons","volume":"741","author":"Donnerer","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.ejps.2025.107314_bib0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0275-5408(00)00011-9","article-title":"Clinical grading of corneal staining of non-contact lens wearers","volume":"21","author":"Dundas","year":"2001","journal-title":"Ophthalmic. Physiol. Opt."},{"key":"10.1016\/j.ejps.2025.107314_bib0008","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40259-013-0079-5","article-title":"Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial","volume":"28","author":"Ferrari","year":"2014","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejps.2025.107314_bib0009","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1159\/000525923","article-title":"Neurotrophic keratopathy treated with topical recombinant human nerve growth factor (Cenegermin): case series study with long-term follow-up","volume":"13","author":"Garc\u00eda-Delpech","year":"2022","journal-title":"Case Rep. Ophthalmol."},{"key":"10.1016\/j.ejps.2025.107314_bib0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.18240\/ijo.2023.01.09","article-title":"Clinical observation of recombinant human nerve growth factor in the treatment of neurotrophic keratitis","volume":"16","author":"Hao","year":"2023","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.ejps.2025.107314_bib0011","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/ICU.0000000000000766","article-title":"The management of neurotrophic keratitis","volume":"32","author":"Jabbour","year":"2021","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.ejps.2025.107314_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.796854","article-title":"New pharmacological approaches for the treatment of neurotrophic Keratitis","volume":"13","author":"Koay","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107314_bib0013","first-page":"1963","article-title":"Growth factors modulate clonal growth and differentiation of cultured rabbit limbal and corneal epithelium","volume":"34","author":"Kruse","year":"1993","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejps.2025.107314_bib0014","first-page":"1154","article-title":"The nerve growth factor 35 years later","volume":"237","author":"Levi-Montalcini","year":"1987","journal-title":"Science (1979)"},{"key":"10.1016\/j.ejps.2025.107314_bib0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00347-018-0823-9","article-title":"Pathogenesis and epidemiology of neurotrophic keratopathy]","volume":"116","author":"Mertsch","year":"2019","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.ejps.2025.107314_bib0016","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cytogfr.2004.09.003","article-title":"Nerve growth factor involvement in the visual system: implications in allergic and neurodegenerative diseases","volume":"15","author":"Micera","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejps.2025.107314_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18051028","article-title":"NGF and its receptors in the regulation of inflammatory response","volume":"18","author":"Minnone","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2025.107314_bib0018","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s41687-020-00192-y","article-title":"Development of the neurotrophic keratopathy questionnaire: qualitative research","volume":"4","author":"Murray","year":"2020","journal-title":"J. Patient. Rep. Outcomes."},{"key":"10.1016\/j.ejps.2025.107314_bib0019","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/07853890.2022.2045035","article-title":"Neurotrophic keratopathy: current challenges and future prospects","volume":"54","author":"NaPier","year":"2022","journal-title":"Ann. Med."},{"key":"10.1016\/j.ejps.2025.107314_bib0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2019.08.020","article-title":"Topical recombinant human nerve growth factor (Cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial","volume":"127","author":"Pflugfelder","year":"2020","journal-title":"Ophthalmology."},{"key":"10.1016\/j.ejps.2025.107314_bib0021","article-title":"The use of rh-NGF in the management of neurotrophic keratopathy","volume":"4","author":"Roszkowska","year":"2024","journal-title":"Front. Ophthalmol. (Lausanne)"},{"key":"10.1016\/j.ejps.2025.107314_bib0022","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jtos.2019.11.008","article-title":"Neurotrophic keratitis: frequency, etiologies, clinical management and outcomes","volume":"18","author":"Saad","year":"2020","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.ejps.2025.107314_bib0023","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0006-8993(98)01094-4","article-title":"Regenerative effect of human recombinant NGF on capsaicin-lesioned sensory neurons in the adult rat","volume":"815","author":"Schicho","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.ejps.2025.107314_bib0024","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/EB.S117261","article-title":"Neurotrophic keratitis: current challenges and future prospects","volume":"10","author":"Versura","year":"2018","journal-title":"Eye Brain"},{"key":"10.1016\/j.ejps.2025.107314_bib0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/OPX.0b013e31815ed756","article-title":"Superficial punctate fluorescein staining of the ocular surface","volume":"85","author":"Ward","year":"2008","journal-title":"Optom. Vis. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:11:22Z","timestamp":1763662282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725003124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"alternative-id":["S0928098725003124"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107314","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and pharmacokinetics of escalating doses of recombinant human nerve growth factor eye drops (HT006.2.2) in healthy subjects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107314"}}